Geode Capital Management LLC Has $5.53 Million Stock Holdings in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

Geode Capital Management LLC raised its holdings in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 8.4% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 3,523,971 shares of the biopharmaceutical company’s stock after buying an additional 273,436 shares during the quarter. Geode Capital Management LLC owned 1.43% of Lexicon Pharmaceuticals worth $5,534,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp grew its stake in shares of Lexicon Pharmaceuticals by 37.6% in the second quarter. Bank of New York Mellon Corp now owns 401,908 shares of the biopharmaceutical company’s stock worth $675,000 after acquiring an additional 109,902 shares during the last quarter. Principal Financial Group Inc. grew its position in Lexicon Pharmaceuticals by 116.1% in the 2nd quarter. Principal Financial Group Inc. now owns 22,759 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 12,225 shares during the last quarter. Rhumbline Advisers increased its holdings in shares of Lexicon Pharmaceuticals by 13.3% during the 2nd quarter. Rhumbline Advisers now owns 152,785 shares of the biopharmaceutical company’s stock worth $257,000 after purchasing an additional 17,940 shares during the period. Victory Capital Management Inc. raised its position in shares of Lexicon Pharmaceuticals by 44.5% during the second quarter. Victory Capital Management Inc. now owns 45,341 shares of the biopharmaceutical company’s stock valued at $76,000 after buying an additional 13,972 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Lexicon Pharmaceuticals by 52.3% in the second quarter. Dimensional Fund Advisors LP now owns 76,086 shares of the biopharmaceutical company’s stock valued at $128,000 after buying an additional 26,143 shares during the period. 74.70% of the stock is owned by institutional investors.

Lexicon Pharmaceuticals Price Performance

Shares of LXRX stock opened at $0.79 on Friday. The stock’s fifty day simple moving average is $0.96 and its 200 day simple moving average is $1.49. Lexicon Pharmaceuticals, Inc. has a one year low of $0.62 and a one year high of $3.73. The firm has a market cap of $194.18 million, a price-to-earnings ratio of -1.05 and a beta of 1.06. The company has a debt-to-equity ratio of 0.56, a current ratio of 7.45 and a quick ratio of 7.43.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.01). Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%. The firm had revenue of $1.75 million during the quarter, compared to the consensus estimate of $3.14 million. During the same period in the previous year, the company posted ($0.21) EPS. On average, analysts expect that Lexicon Pharmaceuticals, Inc. will post -0.66 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on LXRX shares. Leerink Partners set a $6.00 price target on Lexicon Pharmaceuticals and gave the company an “outperform” rating in a research note on Friday, October 18th. HC Wainwright restated a “buy” rating and set a $6.00 price objective on shares of Lexicon Pharmaceuticals in a research report on Wednesday, November 13th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Monday, December 23rd. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $6.00.

Lexicon Pharmaceuticals Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.